May 11 (Reuters) - Fusion Pharmaceuticals Inc FUSN.O :
* Q1 LOSS PER SHARE $0.42
* Q1 EARNINGS PER SHARE ESTIMATE $-0.29 -- REFINITIV IBES DATA
* PHASE 1 STUDY OF FPI-1434 PHASE 1 ENROLLMENT CONTINUES ON TRACK FOR DATA IN H1 2022
* FUSION PHARMACEUTICALS - EXPECTS CASH, CASH EQUIVALENTS & INVESTMENTS AS OF MARCH 31, 2021 WILL ENABLE CO TO FUND ITS OPERATIONS THROUGH END OF 2023